Brent Rexer
Faculty Member
Last active: 2/13/2015

  1. Outsmarting cancer: the power of hybrid genomic/proteomic biomarkers to predict drug response. Rexer BN, Arteaga CL (2014) Breast Cancer Res 16(2): 303
    › Primary publication · 25032256 (PubMed) · PMC4053204 (PubMed Central)
  2. Evaluating HER2 amplification status and acquired drug resistance in breast cancer cells using Raman spectroscopy. Bi X, Rexer B, Arteaga CL, Guo M, Mahadevan-Jansen A (2014) J Biomed Opt 19(2): 025001
    › Primary publication · 24496495 (PubMed) · PMC3913568 (PubMed Central)
  3. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells. Rexer BN, Chanthaphaychith S, Dahlman K, Arteaga CL (2014) Breast Cancer Res 16(1): R9
    › Primary publication · 24451154 (PubMed) · PMC3978602 (PubMed Central)
  4. Phosphatase and tensin homolog deficiency and resistance to trastuzumab and chemotherapy. Rexer BN, Shyr Y, Arteaga CL (2013) J Clin Oncol 31(17): 2073-5
    › Primary publication · 23650407 (PubMed)
  5. Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications. Rexer BN, Arteaga CL (2013) Cancer Res 73(13): 3817-20
    › Primary publication · 23794708 (PubMed) · PMC3702635 (PubMed Central)
  6. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2. Rexer BN, Ghosh R, Narasanna A, Estrada MV, Chakrabarty A, Song Y, Engelman JA, Arteaga CL (2013) Clin Cancer Res 19(19): 5390-401
    › Primary publication · 23948973 (PubMed) · PMC3809918 (PubMed Central)
  7. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, Sánchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL (2013) Cancer Res 73(13): 4075-85
    › Primary publication · 23633485 (PubMed) · PMC3702683 (PubMed Central)
  8. Optical imaging of metabolism in HER2 overexpressing breast cancer cells. Walsh A, Cook RS, Rexer B, Arteaga CL, Skala MC (2012) Biomed Opt Express 3(1): 75-85
    › Primary publication · 22254170 (PubMed) · PMC3255344 (PubMed Central)
  9. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Rexer BN, Arteaga CL (2012) Crit Rev Oncog 17(1): 1-16
    › Primary publication · 22471661 (PubMed) · PMC3394454 (PubMed Central)
  10. Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer. Yang X, Turke AB, Qi J, Song Y, Rexer BN, Miller TW, Jänne PA, Arteaga CL, Cantley LC, Engelman JA, Asara JM (2011) Cancer Res 71(18): 5965-75
    › Primary publication · 21775521 (PubMed) · PMC3209668 (PubMed Central)